辅助化疗对高危软组织肉瘤患者生存的影响:单中心经验。

Q2 Medicine

Journal of Buon Pub Date : 2021-09-01

Ermrah Eraslan, Aysegul Ilhan Gulesen, Fatih Yildiz, Gulnihal Tufan, Ulku Yalcintas Arslan, Necati Alkis

{"title":"辅助化疗对高危软组织肉瘤患者生存的影响:单中心经验。","authors":"Ermrah Eraslan, Aysegul Ilhan Gulesen, Fatih Yildiz, Gulnihal Tufan, Ulku Yalcintas Arslan, Necati Alkis","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the effect of adding adjuvant ifosfamide/doxorubicin combination chemotherapy (CTX) to adjuvant radiotherapy (RT) on the survival in patients with surgically treated high-risk soft tissue sarcomas (STSs).Methods: The study included 69 patients (group A) receiving adjuvant RT and 74 patients (group B) receiving adjuvant CTX after adjuvant RT.Results: The median relapse-free survival (RFS) was 18.2 months (95% CI, 11.9-43.4) in group A and 27.2 months (95% CI, 17.6-36.8) in group B (p = 0.004). The median overall survival (OS) was 45.6 months (95% CI, 26.4-64.8) in group A and 110.1 mo (95% CI, 44.3-175.8) in group B (p = 0.007). Receiving adjuvant CTX was an independent predictive factor for both RFS [HR: 0.482, (0.307-0.757), p = 0.002) and OS (HR: 0.549, [0.348-0.867], p = 0.010).Conclusion: There are conflicting literature data regarding the survival benefit of adjuvant CTX for surgically treated STSs. However, appropriate patient selection may provide a significant survival benefit in RFS and OS with CTX in the adjuvant treatment of high-risk STSs.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience.\",\"authors\":\"Ermrah Eraslan, Aysegul Ilhan Gulesen, Fatih Yildiz, Gulnihal Tufan, Ulku Yalcintas Arslan, Necati Alkis\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To evaluate the effect of adding adjuvant ifosfamide/doxorubicin combination chemotherapy (CTX) to adjuvant radiotherapy (RT) on the survival in patients with surgically treated high-risk soft tissue sarcomas (STSs).Methods: The study included 69 patients (group A) receiving adjuvant RT and 74 patients (group B) receiving adjuvant CTX after adjuvant RT.Results: The median relapse-free survival (RFS) was 18.2 months (95% CI, 11.9-43.4) in group A and 27.2 months (95% CI, 17.6-36.8) in group B (p = 0.004). The median overall survival (OS) was 45.6 months (95% CI, 26.4-64.8) in group A and 110.1 mo (95% CI, 44.3-175.8) in group B (p = 0.007). Receiving adjuvant CTX was an independent predictive factor for both RFS [HR: 0.482, (0.307-0.757), p = 0.002) and OS (HR: 0.549, [0.348-0.867], p = 0.010).Conclusion: There are conflicting literature data regarding the survival benefit of adjuvant CTX for surgically treated STSs. However, appropriate patient selection may provide a significant survival benefit in RFS and OS with CTX in the adjuvant treatment of high-risk STSs.\",\"PeriodicalId\":50248,\"journal\":{\"name\":\"Journal of Buon\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Buon\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的:探讨在辅助放疗(RT)的基础上加用辅助异环磷酰胺/阿霉素联合化疗(CTX)对手术治疗高危软组织肉瘤(STSs)患者生存率的影响。方法:A组69例患者接受辅助放疗，B组74例患者在辅助放疗后接受辅助CTX治疗。结果:A组中位无复发生存期(RFS)为18.2个月(95% CI, 11.9 ~ 43.4)， B组中位无复发生存期(RFS)为27.2个月(95% CI, 17.6 ~ 36.8) (p = 0.004)。A组的中位总生存期(OS)为45.6个月(95% CI, 26.4-64.8)， B组为110.1个月(95% CI, 44.3-175.8) (p = 0.007)。接受辅助CTX治疗是RFS (HR: 0.482， (0.307-0.757)， p = 0.002)和OS (HR: 0.549， [0.348-0.867]， p = 0.010)的独立预测因素。结论:关于辅助CTX对手术治疗的STSs的生存益处，文献数据存在矛盾。然而，在高危STSs的辅助治疗中，适当的患者选择可能会为RFS和OS提供显着的生存益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

The effect of adjuvant chemotherapy on the survival of patients with high-risk soft tissue sarcomas: Single center experience.

Purpose: To evaluate the effect of adding adjuvant ifosfamide/doxorubicin combination chemotherapy (CTX) to adjuvant radiotherapy (RT) on the survival in patients with surgically treated high-risk soft tissue sarcomas (STSs).

Methods: The study included 69 patients (group A) receiving adjuvant RT and 74 patients (group B) receiving adjuvant CTX after adjuvant RT.

Results: The median relapse-free survival (RFS) was 18.2 months (95% CI, 11.9-43.4) in group A and 27.2 months (95% CI, 17.6-36.8) in group B (p = 0.004). The median overall survival (OS) was 45.6 months (95% CI, 26.4-64.8) in group A and 110.1 mo (95% CI, 44.3-175.8) in group B (p = 0.007). Receiving adjuvant CTX was an independent predictive factor for both RFS [HR: 0.482, (0.307-0.757), p = 0.002) and OS (HR: 0.549, [0.348-0.867], p = 0.010).

Conclusion: There are conflicting literature data regarding the survival benefit of adjuvant CTX for surgically treated STSs. However, appropriate patient selection may provide a significant survival benefit in RFS and OS with CTX in the adjuvant treatment of high-risk STSs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.